GH Research (NASDAQ:GHRS) Posts Earnings Results, Beats Estimates By $0.06 EPS

GH Research (NASDAQ:GHRSGet Free Report) announced its earnings results on Thursday. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.06, Zacks reports.

GH Research Stock Performance

Shares of NASDAQ:GHRS traded down $0.08 during midday trading on Friday, reaching $10.58. The company had a trading volume of 38,957 shares, compared to its average volume of 636,491. The company has a fifty day simple moving average of $10.44 and a two-hundred day simple moving average of $9.20. The firm has a market cap of $550.20 million, a price-to-earnings ratio of -13.37 and a beta of 0.93. GH Research has a 1-year low of $6.00 and a 1-year high of $20.50.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Canaccord Genuity Group dropped their price objective on GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of GH Research in a research report on Monday, January 27th. Stifel Nicolaus raised their price objective on shares of GH Research from $18.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Cantor Fitzgerald started coverage on shares of GH Research in a research note on Thursday, February 13th. They issued an “overweight” rating and a $14.00 price objective on the stock. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $30.60.

View Our Latest Stock Analysis on GHRS

About GH Research

(Get Free Report)

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

Featured Stories

Earnings History for GH Research (NASDAQ:GHRS)

Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.